ProCE Banner Activity

A Pharmacologic View of Tardive Dyskinesia: Pathology and Treatment

Slideset

This downloadable slideset revisits the mechanism of action, molecular differences, and PK/PD of VMAT2 inhibitors. Clinical considerations for safety and efficacy in older patient populations as they relate to dosing/titration schedules in special populations with age-related changes in body composition, metabolism, and comorbidities are discussed.

Released: November 27, 2024

Expiration: November 26, 2025

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.